Running title: miR-486 as a tumor suppressor in gastric cancer
Introduction
Gastric cancer (GC) is the second leading cause of global cancer mortality with a particularly high incidence in many Asian countries (1) . Most GC patients are diagnosed with advanced stage disease and show extremely poor prognosis (2) . The 5-year survival rate for patients with stage II disease ranges from 30-50%, falling to 10-25% for Stage III patients (3, 4) . Disease recurrence is also common, with <20% of late stage patients surviving beyond five years (3, 4) . Despite a global decline in incidence, GC remains a disease of outstanding morbidity and mortality. Achieving a better understanding of recurrent molecular aberrations associated with GC carcinogenesis might identify new diagnostic and treatment strategies for this disease.
Genetic factors implicated in GC development include somatic mutations in classical tumor suppressor genes and oncogenes (p53, beta-catenin), gene amplifications and deletions (eg c-Met and ERBB2), and epigenetic inactivation of
CDKN2A (p16), CDH1 (E-cadherin), hMLH1, and RUNX3 (5, 6) . Besides protein coding genes, recent evidence has demonstrated an important role for non-coding RNAs in human cancer and in particular microRNAs (miRNAs) (7) . miRNAs are naturally occurring small RNA molecules of ~22-nucleotides (8) which base-pair with complementary sequences located in the 3'untranslated regions (UTRs) of target genes, causing either target mRNA degradation or reduced protein translation (9, 10 ).
An individual miRNA can regulate a large number of target mRNAs (11) , and conversely a single gene may be regulated by multiple independent miRNAs. The ability of miRNAs to affect multiple downstream target genes suggests that miRNAs may be particularly adept at broadly modulating the activity of multiple cellular pathways (9, 10) . In cancer, miRNAs can exert either oncogenic or tumor suppressive roles (12) . Oncogenic miRNAs such as miR -21, mir-155, mir-17-92 , and miR-372/miR-373 are frequently upregulated in tumors and can negatively regulate tumor suppressor genes such as Bim, PTEN, and LATS2 (12) (13) (14) . Conversely, tumor suppressive miRNAs, which are usually underexpressed in tumors, have been shown to inhibit oncogenes such as RAS, BCL2 and MYC (12) . Some examples of tumor suppressor miRNAs include let-7, mir-15 and mir- 16. In GC, several miRNA profiling studies have been reported (15) (16) . However, most of these previous studies have largely focused on characterizing oncogenic miRNAs (eg miR-21, miR-27a and the miR106b-25 cluster) (17) (18) (19) . In contrast, relatively few tumor suppressor miRNAs in GC are known, and while candidates such as miR-141, miR-143, miR-145, miR-9 and miR-218 have been proposed as possible tumor suppressor miRNAs, their functions and target genes have not been extensively explored (20) (21) (22) (23) (24) . Here, we compared miRNA expression profiles of gastric tumors and matched normal tissues to identify hsa-miR-486-5p (miR-486) as a significantly downregulated miRNA in GC. Subsequent functional characterization revealed that miR-486 inactivation is required for the expression of several pro-oncogenic traits, which may involve miR-486 targeting the OLFM4 anti-apoptotic factor. Importantly, we observed frequent and focal genomic deletions of the miR-486 locus in 20-30% of GCs, consistent with miR-486 playing a tumor suppressor role. Finally, miR-486 downregulation has also been observed in several other human cancers (25) , it is thus possible that miR-486 may exert important tumor suppressive functions in other cancer types besides GC. 
Materials and Methods

Primary
miRNA Expression Profiling
Total RNA was extracted from primary tissues and cell lines using the miRVana miRNA Isolation Kit (Ambion, Inc, Austin,TX,USA) according to the manufacturer's instructions. RNA samples were hybridized to Agilent Human miRNA Microarrays (V2) representing 723 human and 76 human viral miRNAs, and scanned using an Agilent DNA Microarray Scanner (Model G2565BA). miRNA expression values were normalized against background signals using Feature Extraction Software 7 (Agilent). The miRNA data was also subjected to a log 10 transformation followed by median centering across probes, prior to in-depth analysis. The miRNA expression data has been deposited into GEO under accession number GSE23739.
(The reviewer's link is http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=lfonrsseimicalw&acc=GSE23 739)
Microarray Data Analysis
Differentially expressed microRNAs were identified using the Significance Analysis 
Results
Identification of Differentially Regulated microRNAs in Primary Gastric
Tumors
To identify miRNAs exhibiting expression changes in GC, we profiled 40 gastric tumors and 40 non-cancerous gastric tissues on Agilent miRNA microarrays measuring ~800 miRNAs (723 human and 76 viral miRNAs). Gastric tumors are traditionally classified by histology into 2 major groups -intestinal (expanding, or differentiated), and diffuse (infiltrative or undifferentiated) (26) . Our analysis covered both GC subtypes, since half of the tumors were intestinal-type GC (20 samples), while the other half were diffuse-type cancers. An initial unsupervised analysis where the gastric samples were clustered using miRNAs detectibly expressed in 25% of the samples (329 probes) resulted in an overall partitioning of gastric tumors away from normals, indicating the existence of pervasive miRNA expression differences between the two groups (Fig. S1) . We focused our analysis on miRNAs exhibiting striking differences in expression between gastric normals and tumors. Using Significance Analysis of Microarrays (SAM), we identified 80 miRNAs that were significantly differentially expressed between the two groups (FDR<0.01) (Fig. 1A , Supplemental Table S1 provides a list of the top 80 miRNAs).
We divided the differentially regulated miRNAs into three distinct classes functions in multiple cancer types including GC (17, 18) . The re-identification of these known oncogenic miRNAs supports the biological validity of the miRNA microarray data. Interestingly, we also observed upregulation of hsa-miR-16 and hsa-miR-214 in GC, two miRNAs being previously reported to be down-regulated in prostate and cervical cancers (27, 28) . It is thus possible that certain miRNAs may exert either pro or anti-oncogenic functions that are dependent on tissue type.
The second class comprised miRNAs exhibiting downregulation in tumors relative to normals -such miRNAs might represent candidates for potential tumorsuppressor miRNAs. Given the relative lack of validated tumor suppressor miRNAs in GC compared to oncogenic miRNAs, we decided to focus on this list for further analysis. Using multiple filtering criteria (see Methods); we nominated a set of 16 candidate tumor-suppressor miRNAs (Fig. 1B) . Providing confidence in our filtering criteria, among the 16 candidates we re-identified mir-375, a known tumor suppressor miRNA in GC (29) . These miRNAs are further considered in the next section.
We also detected a third and smaller class of miRNAs that were differentially expressed between intestinal and diffuse-type GCs (Fig.1A , bottom panel). In general, these miRNAs (hsa-let7d*, hsa-miR-328, hsa-miR-32*, hsa-miR-1227, hsa-miR-206, hsa-miR-1229, hsa-miR-595 and hsa-miR-631) were largely downregulated in diffusetype GC compared to intestinal-type GCs. Although not the primary focus on this study, these results raise the possibility that differences in miRNA expression may also exist between the two major histologic subtypes of GC.
Expression Patterns of miR-486, a Candidate Tumor Suppressor miRNA in GC
Hypothesizing that some of the 16 nominated miRNAs exhibiting decreased expression in GC might represent bona-fide GC tumor suppressors, we selected a handful for functional validation. Here, we report our findings for the first of these candidates, hsa-miR-486-5p, hence after referred to as miR-486. miR-486 is located on chromosome 8p11 within intron 41 of the Ankyrin-1 (Ank1) gene ( 
Migration, and Invasion in GC Cells
To investigate the functional significance of miR-486 downregulation in GC, we selected three GC cell lines (YCC3, AGS and SCH) for further studies as these three lines express low levels of miR-486 (Fig. 2D) . Synthetic miR-486 precursor molecules were transfected into these cells lines to restore miR-486 expression, and restoration of miR-486 expression in these cells was confirmed by qRT-PCR (Fig.   3A) . First, we compared the cell proliferation rates of control and miR-486 transfected cells at various time points. In all three cell lines, the growth of miR-486 transfected cells was significantly reduced compared to cells transfected with negative-control miRs (Fig.3B ). This result suggests that restoring miR-486 expression is sufficient to inhibit cellular proliferation in GC.
Second, to examine the importance of miR-486 in the tumorigenesis of GC cells, we performed anchorage-independent growth assays. Using a blasticidin selection protocol (see Methods), we generated stable pools of SCH, YCC3 and AGS cells expressing miR-486 or empty vector controls. SCH and YCC3 cells transfected with empty vector controls grew well in soft agar, forming distinct colonies (Fig. 3C ).
In contrast, SCH and YCC3 cells expressing miR-486 exhibited a dramatic reduction in the number of soft agar colonies (Fig. 3C) , demonstrating transforming abilities less than 50% of the control cells. Similar data was obtained for AGS cells ( controls migrated robustly in Transwell assays (Fig. 3D, top) , while AGS cells overexpressing miR-486 exhibited a significant reduction in migration capacity (p<0.05, about 2-fold). Similarly, in invasion assays, AGS cells overexpressing miR-486 exhibited a 2-fold reduced capacity for invasion compared to controls (p=0.05) (Fig. 3D, bottom) . Besides epigenetic silencing (31), genomic loss is another mechanism by which tumor suppressor miRNAs can be downregulated in cancer (32) . Notably, miR-486 is located on chromosome 8p11, a frequent region of loss-of-heterozygosity in many cancers, including gastric cancer (33, 34) . While ANK1, the gene within which miR- 
ARID1A
) have been previously shown to be associated with tumor suppressive functions (36, 37) . More importantly, we identified SP5 and OLFM4, as potential prooncogenic miR-486 target genes (38, 39) . Our attention was specifically drawn to OLFM4 (Olfactomedin-4/GW112), as OLFM4 has been previously reported to be highly expressed in gastric tumors and specifically gastric cancer cells compared to normal tissues (39) (40) (41) . Both prediction programs identified one potential miR-486 binding site in the OLFM4 3'UTR.
Functionally, OLFM4 has also been shown to behave as an anti-apoptotic factor and to promote tumor growth and invasion (see Discussion) (42, 43) .
Confirming previous reports, we found that OLFM4 was indeed highly expressed in GCs compared to gastric normals (p<0.001) (Fig. 5B) . Also supporting recent findings, the high expression of OLFM4 in tumors was largely associated with intestinal-type GCs (Table 1) (40) . No significant associations were observed between OLFM4 expression with tumor stage, grade, or patient survival (data not shown).
To investigate relationships between endogenous miR-486 and OLFM4
expression, we analyzed 11 intestinal-type primary GCs and matched non-malignant tissues for which both miR-486 and OLFM4 expression were available. miR-486 was significantly negatively correlated to OLFM4 expression (R=-0.619, p=0.0031) ( We then performed luciferase reporter assays to demonstrate a direct functional role of the predicted miR-486 binding sites in the OLFM4 3'-UTR.
Luciferase reporters were constructed containing either a wild-type OLFM4 3'-UTR sequence containing the miR-486 binding site (WT-UTR), or a mutated OLFM4 3'UTR where the miR-486 seed sequence binding sites were altered (MUT-UTR) (Fig.5E) . The WT-UTR and MUT-UTR luciferase reporter constructs were transfected into GC cells, along with miR-486 or negative control miRNAs.
Luciferase expression of the WT-UTR reporter was significantly decreased compared to MUT-UTR (p<0.05) or vector-expressing cells in a miR-486-dependent manner, indicating that miR-486 is able to reduce the reporter activity of WT-UTR but not MUT-UTR (Fig. 5E ). This result strongly indicates that that miR-486 directly targets the OLFM4 3'UTR, resulting in the translation inhibition of OLFM4 protein.
OLMF4 Expression Promotes GC cell proliferation and Inhibits the Anti-
Oncogenic Effects of miR-486
OLFM4 has been proposed to promote tumor growth by functioning as an anti-apoptotic protein (42, 43) attenuating the apoptotic function of GRIM-19, a celldeath regulatory protein. To establish a functional role for OLFM4 in GC, we silenced OLFM4 in YCC3 and SCH cells, and conducted cell proliferation assays.
OLFM4-silenced YCC3 and SCH cells exhibited significantly slower cellular
proliferation compared to control-siRNA treated cells (Fig. 5F ). This result suggests that OLFM4 activity may be required for GC development and progression.
Interestingly, downregulation of OLFM4 by miR-486 also resulted in up-regulation of GRIM-19, the proposed target of OLFM4 (Fig. S3) . were transfected with OLMF4 expressing constructs. We found that Y4 cells overexpressing OLMF4 exhibited a significant increase in cell proliferation compared to control Y4 cells, comparable to parental YCC3 cells (Fig. S4) . These results suggest that the tumor-suppressive effects of miR-486 are likely to be mediated, at least in part, through its effect on OLFM4 activity. In summary, our data suggests that The exact mechanisms causing miR-486 down-regulation in cancers deserve further study. In the current study, we found that about 25-30% of gastric tumors, exhibited a genomic loss of the chromosome 8p11 region where miR-486 is located.
This frequency of 8p loss is comparable to previous array-based CGH studies of GC (44, 45) . Moreover, genomic deletions in miRNAs have been reported as a mechanism for miRNA downregulation, as shown for miR-101, miR-15a, and miR-16-1 (32, 46 
genomic deletions alone are unlikely to fully explain the pervasive downregulation of miR-486 in GC. It is thus almost certain that other GC tumors must employ alternative mechanisms to achieve miR-486 downregulation, such as for example epigenetic silencing or transcriptional repression, as reported for miR-124 (47) or transcriptional suppression of the miR-29a promoter by myc (48) . In our study, we did not observe evidence of miR-486 epigenetic regulation when GC cell lines were treated with either inhibitors of DNA methyltransferanse or histone acetyltransferases, however these experiments were far from exhaustive. More work is thus required to fully delineate the spectrum of mechanisms responsible for miR-486 downregulation in GC.
Our study suggests that OLFM4 is likely a direct target gene of miR-486.
However, it is likely over-simplistic to expect that the anti-oncogenic effects of miR-486 can be entirely explained by its ability to regulate a single gene alone, particularly since previous studies investigating the cellular functions of miRNAs have shown that a single miRNA can often regulate many genes and gene targets (11) . Besides OLFM4, our bio-informatic analysis we identified 16 other potential miR-486 target genes, several of which may function in cancer (eg FBN1, HAT1, SP5, TOB1, ARID1A and OLFM4), and miR-486 has also been shown to target PTEN in muscle cells (30) . Nevertheless, OLFM4 is likely to be a biologically relevant miR-486 target in the context of GC. OLFM4 has been reported to be overexpressed in various cancers including GC but also colon, breast and lung cancers (41) , and has been proposed as a potential serum biomarker of GC (39) . Functionally, OLFM4 has been shown to interact with GRIM19 (a cell-death regulatory protein), cadherins and lectins, and OLFM4 has been shown to inhibit apoptosis and promote tumor growth and invasion (41) (42) (43) . However, a recent finding showed that OLFM4 has a proapoptotic effect in myeloid leukemia cells (49) . In our study, the biological relevance it is intriguing to note that OLFM4 has also been recently reported to be a robust marker of intestinal stem cells (50).
In conclusion, our data suggests that miR-486 may act as a novel tumor suppressor miRNA in GC, and that its down-regulation in gastric tumors, may be 
